Pegfilgrastim subcutaneous injection 3.6mg Drug use results survey -Prevention of chemotherapy-induced febrile neutropenia-

Pegfilgrastim subcutaneous injection 3.6mg Drug use results survey -Prevention of chemotherapy-induced febrile neutropenia- - Pegfilgrastim subcutaneous injection 3.6mg Drug use results survey -Prevention of chemotherapy-induced febrile neutropenia-

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000054267

Enrollment

1500

Registered

2024-04-27

Start date

2015-08-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients who received pegfilgrastim for the first time to prevent of chemotherapy-induced febrile neutropenia

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who received pegfilgrastim for the first time to prevent of chemotherapy-induced febrile neutropenia

Exclusion criteria

Exclusion criteria: -If a contract with the facility has not been concluded -If the start date of Pegfilgrastim administration is outside the contract period -If there are duplicate registered cases (already registered) -If the number of registrations exceeds the number of contracted cases -If the case is registered after Pegfilgrastim administration -If registered by a doctor other than the contracted doctor

Design outcomes

Primary

Measure	Time frame
Consider the following safety issues -Side effects/infectious diseases (types, incidence, etc.) -Factors that may affect safety -Serious adverse events -Safety specifications Consider the following effectiveness issues -Febrile neutropenia -Changes in neutrophil count -Examination of factors thought to influence changes in neutrophil count and the onset of febrile neutropenia	—

Countries

Japan

Contacts

Public ContactHiroshi Kuwazawa

Kyowa Kirin Co., Ltd. Pharmacovigilance Division

hiroshi.kuwazawa.wd@kyowakirin.com07031439628

Outcome results